Catalysts / IONS
Upcoming FDA decisions and readouts we track for Ionis Pharmaceuticals, each with the filing that announced it.
FreeBioList tracks 2 catalysts for Ionis Pharmaceuticals (IONS, listed on Nasdaq): 1 upcoming and 1 decided. They cover 2 programmes: Zilganersen (Alexander disease) and Bepirovirsen (Chronic hepatitis B).
First on the list: the PDUFA date for Bepirovirsen (Chronic hepatitis B), dated 26 Oct 2026.
Decided and on record:
Each outcome links to the filing or notice that reported it in the table below.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 14 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals IONS · Nasdaq | Zilganersen | Alexander disease | 22 Sep 2026 15d ago |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Ionis Pharmaceuticals IONS · Nasdaq | Bepirovirsen | Chronic hepatitis B | 26 Oct 2026 in 19d |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList